We evaluated the efficacy of low-dosed rituximab, a B cell depleting therapy, which was used in combination with mycophenolate mofetil (MMF) in our cohort of patients with SLE and GPA with refractory disease and severe organ involvement. During the follow up of patients, repeated low-dosed Rituximab boli were given in case of increasing disease activity and recurrence of B-cells in the peripheral blood. Rituximab in combination with MMF proved to be effective for the treatment of severe and refractory SLE and GPA.
«
We evaluated the efficacy of low-dosed rituximab, a B cell depleting therapy, which was used in combination with mycophenolate mofetil (MMF) in our cohort of patients with SLE and GPA with refractory disease and severe organ involvement. During the follow up of patients, repeated low-dosed Rituximab boli were given in case of increasing disease activity and recurrence of B-cells in the peripheral blood. Rituximab in combination with MMF proved to be effective for the treatment of severe and refr...
»